Skip to main content
. Author manuscript; available in PMC: 2013 Dec 24.
Published in final edited form as: Nat Commun. 2013;4:2035. doi: 10.1038/ncomms3035

Figure 3. JIB-04 E-isomer and its analog have selective anti-cancer activity.

Figure 3

(a) Log scale representation of cell viability IC50 values comparing sensitivities of unimmortalized and immortalized prostate (open symbol; PrEC/PrSC) or lung (closed symbol, HBEC) normal cells to prostate cancer (PrCa) or lung cancer (LCa) cells treated with JIB-04 over four days show JIB-04’s selective anti-cancer properties. (b) Cell viability dose response curves for patient matched lines from normal and cancerous lungs treated with JIB-04 over four days confirm JIB-04’s cancer specificity. Error bars represent s.d. across eight replicates. Compare HBEC30KT to HCC4017 and HBEC34KT to HCC4018. (c,d) The LDR active E-isomer but not the inactive Z-isomer potently inhibits LDR carcinoma cell viability (c) and induces apoptosis (d). (e) Cell viability dose response curves for one of the patient matched pair of cell lines shown in (b) are given for dimethyloxalylglycine, D1070, a general inhibitor of α-ketoglutarate. Error bars represent s.d. across eight replicates. HCC4017 IC50=100µM; HBEC30KT IC50=600µM.